| ¿µ¹® | immune system | ÇÑ±Û | ¸é¿ªÃ¼°è |
|---|---|---|---|
| ¼³¸í | ¼¼Æ÷¼ººÐ ¹× ºÐÀÚ¼ººÐÀÇ º¹ÇÕü°è·Î¼, ÀÌÀÇ ÀÏÂ÷±â´ÉÀº ÀÚ±â(self)¸¦ ºñÀÚ±â(not self)·ÎºÎÅÍ ±¸º°ÇÏ°í ¿ÜºÎ»ý¹° ¶Ç´Â ¹°Áú¿¡ ´ëÇØ ¹æ¾îÇÏ´Â °ÍÀÌ´Ù. ÀÏÂ÷ÀûÀÎ ¼¼Æ÷¼ººÐÀº ¸²ÇÁ±¸¿Í Å«Æ÷½Ä¼¼Æ÷À̸ç ÀÏÂ÷ÀûÀÎ ºÐÀÚ¼ººÐÀº Ç×ü¿Í ¸²Æ÷Ä«ÀÎÀÌ´Ù. |
||
| ¿µ¹® | urinary system | ÇÑ±Û | ºñ´¢±â°èÅë |
|---|---|---|---|
| ¼³¸í | ºñ´¢±â°èÅëÀ̶óÇϸé ÄáÆÏÀ¸·ÎºÎÅÍ ½ÃÀÛÇØ¼ ¿ä°ü, ¹æ±¤, ¿äµµ¿¡ À̸£´Â ÀÏ·ÃÀÇ ¿ÀÁÜ»ý¼º ¹× ÀúÀå, ¹è¼³±â°üÀ» ÀÏÄ´´Ù. ÄáÆÏÀº ±æÀÌ ¾à 2.5cm, Æø ¾à 5.1cm, µÎ²² ¾à 2.5cm, ¹«°Ô ¾à 120~160gmÀ¸·Î¼, ³»Ãø¿¡ ÄáÆÏ¹®ÀÌ ÀÖ¾î Ç÷°ü, ½Å°æ, ¿ä°üÀÌ ÃâÀÔÇϰí ÀÖ´Ù. ÄáÆÏÀº ¼ÓÁú°ú °ÑÁú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¼öÁúÀº 10~15°³ÀÇ Ãßü(¿ÀÁÜÀ» ¸ðÀ¸´Â ¿ªÇÒ)¸¦ Çü¼ºÇÏ°í °ÑÁúÀº ¾à 100¸¸°³ÀÇ ÄáÆÏ´ÜÀ§À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¿ä¼¼°üÀº Å丮ÂÊ´¢¼¼°ü, Çî·¹°í¸®, ¸ÕÂÊ´¢¼¼°ü, ÁýÇÕ°üÀ¸·Î Çü¼ºµÇ¾î ÀÖÀ¸¸ç, Ãßü¿Í ¼úÀÜ, ±ò¶§±â¸¦ °ÅÃÄ ¿ä°üÀ¸·Î ¿¬°áµÈ´Ù. ÄáÆÏÀº Ç÷¾×À» ¿©°úÇÏ¿© ½Åü ½ÅÁø´ë»çÀÇ ÃÖÁ¾»ê¹°À» ¿ÀÁÜÀÇ ÇüÅ·Π¹è¼³Çϸç, ¼¼Æ÷¿Ü¾×(extracellular fluid)ÀÇ ÀüÇØÁú³óµµ¸¦ Á¶ÀýÇÑ´Ù. ÄáÆÏ¿¡¼ Çü¼ºµÈ ¿ÀÁÜ´Â ¿ä°üÀ» °ÅÃÄ ¹æ±¤¿¡¼ ÀúÀåµÇ°í ÀÖ´Ù°¡ Àû´çÇÑ ½Ã±â°¡ µÇ¸é ¿äµµ¸¦ ÅëÇØ ¿Ü°è·Î ¹èÃâµÈ´Ù. |
||
| ¿µ¹® | reproductive system | ÇÑ±Û | »ý½Ä±â°èÅë |
|---|---|---|---|
| ¼³¸í | 1.³²¼º»ý½Ä°èÅë: ³²¼º»ý½Ä±â´Â Á¤ÀÚ(sperm)¸¦ »ý¼ºÇÏ´Â °íȯ°ú Á¤ÀÚÀÇ ¼º¼÷, ¿î¹Ý, ±×¸®°í »çÁ¤¿¡ °ü¿©ÇÏ´Â ºÎ°íȯ, Á¤°ü, À½°æ(penis) µîÀ¸·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç, ºÎ¼Ó±â°üÀ¸·Î ¿ÜºÐºñ»ùÀÎ Á¤³¶(seminal vesicle), Àü¸³»ù(prostate), ¿äµµ¸Á¹°»ù(bulbourethral gland, Cowper¡¯s gland) µîÀ» °®Ãß°í ÀÖ´Ù. °íȯÀº Á¤ÀÚ¸¦ »ý»êÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ³²¼ºÈ£¸£¸ó(testosterone)À» ºÐºñÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. °íȯ¿¡¼ ºÐºñµÇ´Â ³²¼ºÈ£¸£¸óÀº Á¤ÀÚ»ý¼º°ú »ý½Ä±âÀÇ ¹ß´Þ ¹× À¯Áö¿¡ ÇʼöÀûÀÎ ¿ªÇÒÀ» ÇϹǷΠ³²¼º»ý½Ä±â´ÉÀÇ ¿øÃµÀº °íȯ¿¡ ÀÖ´Ù°í º¼ ¼ö ÀÖ´Ù. 2.¿©¼º»ý½Ä°èÅë: ¿©¼º»ý½Ä±â´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â ³¼Ò¿Í ³ÀÚ¸¦ ÀÚ±ÃÀ¸·Î ¿î¹ÝÇÏ´Â ³°ü, ±×¸®°í Àڱðú Áú·Î ÀÌ·ç¾îÁ® ÀÖÀ¸¸ç ¿ÜºÐºñ¼±ÀÎ ¹Ù¸£Å縰»ù¸¦ °®Ãß°í ÀÖ´Ù. ³¼Ò´Â ³ÀÚ¸¦ »ý¼ºÇÏ´Â »ý½Ä»ùÀÎ µ¿½Ã¿¡ ¿©¼ºÈ£¸£¸óÀ» ºÐºñÄÉÇÏ´Â ³»ºÐºñ»ùÀÌ´Ù. ¿ù°æÁÖ±â Àü¹ÝºÎ¿¡ ³ÀÚ¸¦ »ý¼º½Ã۱âÀ§ÇØ ¼º¼÷µÇ°í ÀÖ´Â ³Æ÷¿¡¼ ºÐºñµÇ´Â ¿¡½ºÆ®·Î°ÕÀº ¿©¼º 2Â÷ ¼ºÂ¡ÀÇ ¹ß´ÞÀ» °üÀåÇÒ »Ó ¾Æ´Ï¶ó Àڱ󻸷À» ÀåÂ÷ ¼öÁ¤µÉ ¼öÁ¤¶õÀÌ Âø»óÇϱ⿡ ¾Ë¸ÂÀº »óÅ·Π¸¸µé¾îÁØ´Ù. ³ÀÚ°¡ ºÐºñµÇ°í ³²Àº Ȳü¿¡¼ ºÐºñµÇ´Â Ǫ·Î°Ô½ºÅ×·ÐÀº Àڱ󻸷À» º×µµ·Ï ÇÏ¸é ºÐºñ¾×À» Áõ°¡½Ã۸ç ÀڱñÙÀÇ ¼öÃàÀ» ¹æÇØÇÏ¿© ÀӽŽà ÀÓ½ÅÀ» Áö¼Ó½ÃŰ´Â ¿ªÇÒÀ» ÇÑ´Ù. |
||
| ¿µ¹® | digestive system | ÇÑ±Û | ¼Òȱâ°èÅë |
|---|---|---|---|
| ¼³¸í | ¸ÔÀº À½½ÄÀÇ ºÐÇØ, ¼ÒÈ, Èí¼ö¿¡ °ü°èµÈ Àå±â¸¦ ÅëÄªÇØ¼ ºÎ¸£´Â ¸». |
||
| ¿µ¹® | nervous system | ÇÑ±Û | ½Å°æ°è |
|---|---|---|---|
| ¼³¸í | ¿©·¯ ±â°üµéÀÇ ¼·Î°£ »óÈ£¿¬°áü°è°¡ ¹Ù·Î ½Å°æ°èÀÌ´Ù. ¿©±â¿¡´Â ÁßÃ߽Űæ°è(central nerve system: CNS)¿Í ¸»ÃʽŰæ°è(peripheral nerve system: PNS)°¡ Àִµ¥, ÁßÃ߽Űæ°è¶õ ³ú¿Í ô¼ö¸¦ ¸»ÇÑ´Ù. ±×¸®°í ¸»ÃʽŰæ°è¿¡´Â 12½ÖÀÇ ³ú½Å°æ(cranial nerve: ³ú¿¡¼ ±â½ÃÇÏ¿© ÁÖ·Î ¾ó±¼ºÎÀ§¿Í ¸ñ ºÎÀ§¿¡ ºÐÆ÷ÇÑ´Ù)°ú 31½ÖÀÇ Ã´¼ö½Å°æ(spinal nerve:spinal cord¿¡¼ °¢±â ¾çÂÊÀ¸·Î ½ÖÀ» ÀÌ·ç¾î ³ª¿À´Âµ¥ ÁÖ·Î ¸ñÀÌÇϺÎÀ§ÀÇ ½Åü °¢ºÎºÐÀ¸·Î ºÐÆ÷ÇÏ°Ô µÈ´Ù)À¸·Î ±¸¼ºµÇ¾î ÀÖ´Ù. ¶ÇÇÑ ¸»ÃʽŰæ°è´Â 3°¡ÁöÀÇ ½Å°æÁ¶Á÷µé·Î ±¸¼ºµÇ¾î Àִµ¥ ¾Õ¿¡¼ ¸»ÇÑ ³ú½Å°æ°ú ô¼ö½Å°æ¿Ü¿¡ ÀÚÀ²½Å°æ°è°¡ ¿©±â¿¡ ÇØ´çµÈ´Ù. ÀÚÀ²½Å°æ°è´Â ´Ù½Ã ±³°¨½Å°æ°ú ºÎ±³°¨½Å°æÀ¸·Î ³ª´µ¾îÁ® ¼·Î°£ÀÇ ¿Ã¹Ù¸¥ »óÈ£ÀÛ¿ëÀ¸·Î »ýü ¿©·¯ °¡Áö ÀÛ¿ëÀ» ¼öÇàÇÑ´Ù. |
||
| PFT | pancreatic function test; parafascicular thalamotomy; posterior fossa tumor; prednisone, fluorouraci... |
|---|---|
| PNP | pancreatic polypeptide; para-nitrophenol; peak negative pressure; pediatric nurse practitioner; peri... |
| PVP | penicillin V potassium; peripheral vein plasma; peripheral venous pressure; polyvinylpyrrolidone; po... |
| MEOS | Microsomal Ethanol Oxidizing System = MFOS; Mixed Function Oxidase System |
| PFT | 1) Platelet Function Test 2) Pulmonary Function Test |
| urinary organs | Organs involved with the formation, storage, and excretion of urine. Synonym: organa urinaria. (05 Mar 2000) |
|---|---|
| lymph nodes of abdominal organs | The numerous lymph nodes receiving lymph from abdominal organs located in association with the visceral branches of the aorta. Synonym: nodi lymphatici abdominis viscerales. (05 Mar 2000) |
| anti-allergic and respiratory system agents | A collective term for drugs used to treat allergic reactions as well as those drugs that produce an effect on the respiratory system. (12 Dec 1998) |
| retrospective studies | Studies used to test aetiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. (12 Dec 1998) |
| pharmalogical studies | <pharmacology> Studies to assess the potential harmful or other effects of drugs (16 Dec 1997) |
| clinical studies | <pharmacology> Human studies that are designed to measure the safety, efficacy, and appropriate dosage of a new drug or biological. Clinical studies routinely involve the use of a placebo group that is given an inactive substance that looks like the test product. (14 Nov 1997) |
| cohort studies | Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesised to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. (12 Dec 1998) |
| combination studies | <pharmacology> Studies in which a new drug is evaluated in combination with existing drugs. (09 Jan 1998) |
| multicenter studies | Controlled studies which are planned and carried out by several cooperating institutions to assess certain variables and outcomes in specific patient populations, for example, a multicenter study of congenital anomalies in children. (12 Dec 1998) |
| multivariate studies | The use of statistical techniques for the simultaneous investigations of the influence of several variables. (05 Mar 2000) |
| preclinical studies | <pharmacology> Studies in which a drug is tested on animals and in other non-human test systems. Safety information from such studies are used to support an investigational new drug application. (14 Nov 1997) |
| sampling studies | Studies in which a number of subjects are selected from all subjects in a defined population. Conclusions based on sample results may be attributed only to the population sampled. (12 Dec 1998) |
| prospective studies | Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. (12 Dec 1998) |
| his bundle studies | <cardiology> This test studies the electrical activity of the bundle of HIS. The bundle of HIS is a group of electrical fibres in the heart that are responsible for transmitting the electrical impulses which generate a normal cardiac contraction. This test may be performed in cases of cardiac arrhythmias, to locate a specific area responsible for a conduction defect and to determine the need for cardiac pacemaker placement. The test involves the passage of a an electrode tipped catheter into the heart. This catheter is usually threaded through a neck, arm or chest vein. Measurements of the HIS bundle can then be performed while standard ECG leads are placed on the arms and legs. This test carries a small risk of bleeding, arrhythmias, embolism, heart attack and stroke. It is performed by a specially trained cardiologist. (27 Sep 1997) |
| immunofluorescent studies | <technique> A special assay that relies on the production of measurable fluorescent light. An immunofluorescent tagged antibody interacts and binds with an antigen allowing an indirect measurement of its concentration. (27 Sep 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|